Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Salbutamol Sulfate Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Salbutamol Sulfate Injection is primarily used for treating bronchial asthma or wheezing bronchitis and other respiratory diseases associated with bronchospasm [1]

Policy Developments - Shanghai Municipal Drug Administration issued the "Priority Approval Procedure for Class II Medical Devices," allowing certain medical devices to enter a priority approval process based on specific criteria, including those related to rare diseases and urgent clinical needs [2]. Drug and Device Approvals - Eli Lilly's GLP-1 drug Tirzepatide (brand name: Mounjaro) received approval for a new indication in China, allowing its use in conjunction with insulin for adult Type 2 diabetes patients, potentially boosting its revenue [4]. - Dongcheng Pharmaceutical obtained a radioactive drug production license, although it is not expected to significantly impact current performance until further approvals are secured [5]. - Shanghai Pharmaceuticals' salbutamol injection passed the consistency evaluation for generic drugs, indicating its quality and efficacy for treating respiratory diseases [6]. Financial Reports - Qizheng Tibetan Medicine reported a 16.36% increase in total revenue to 1.175 billion yuan and a 9.94% rise in net profit to 358 million yuan for the first half of 2025 [8]. Capital Market Developments - Laimei Pharmaceutical announced a change in its indirect controlling shareholder structure, with Guangxi State-owned Assets Supervision and Administration Commission planning to transfer 33% of Guangtou Group's shares to Guangxi State Control Group without affecting the company's operations [10]. - Hengrui Medicine entered a licensing agreement with GSK for global exclusive rights to the HRS-9821 project and up to 11 additional projects, with potential milestone payments totaling approximately $12 billion [12]. Industry Highlights - Yanshan Technology's subsidiary made breakthroughs in brain-computer interface technology, aiming to enhance communication for patients with speech impairments due to neurological conditions [14]. - The Guangdong Institute of Intelligent Science and Technology announced the launch of the world's first multi-modal dream brain-computer interface device, designed to improve sleep quality and manage health [15]. - Bristol-Myers Squibb received approval for China's first dual immunotherapy for first-line treatment of non-small cell lung cancer, marking a significant advancement in cancer treatment options [16]. Market Movements - Shanghai Zhangjiang Group reduced its stake in MicroPort Medical, selling 37 million shares at approximately HKD 9.84 per share, totaling around HKD 364 million [18].

Core Viewpoint - Warner Pharmaceuticals has received approval from the National Medical Products Administration for the registration certificate of Salbutamol Sulfate Injection, which is intended for the treatment of bronchial asthma and wheezing bronchitis associated with bronchospasm [1] Group 1 - The drug is classified as a Category 3 chemical drug under the new registration classification, indicating it has passed the consistency evaluation [1] - The acquisition of this registration certificate enriches the company's formulation product variety, positively impacting the optimization of the company's product structure [1]